applies molecular profiling and bioinformatics to identify clinically relevant methylation signatures that can be translated into laboratory tests. The products target use cases such as improving risk assessment, informing treatment decisions, and monitoring disease over time. CpG Diagnostics, Inc. collaborates with clinicians, researchers, and healthcare organizations to validate its assays in clinical studies and integrate them into diagnostic workflows. The company also engages with potential partners in diagnostics and biopharma to expand applications of its epigenetic testing approach across additional cancer types and care pathways.